Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.
Skip to main content

Table 3 Risk factors, coronary heart disease and myocardial infarction in haplotypes of the β2-adrenergic receptor.

From: Risk factors and myocardial infarction in patients with obstructive sleep apnea: impact of β2-adrenergic receptor polymorphisms

 

All

     
  

Haplotype 1

Haplotype 2

Haplotype 3

Haplotype 4

Haplotype 5

n (%)

429

113 (26.3)

78 (18.2)

47 (11.0)

42 (9.8)

34 (7.9)

Diabetes, n (% of Hap.)

74 (17.2)

21 (18.6)

12 (15.4)

7 (14.9)

10 (23.8)

5 (14.7)

Hypertension,, n (% of pt)

258 (60.1)

70 (61.9)

48 (61.5)

25 (53.2)

24 (57.1)

21 (61.8)

Dyslipidemia n (% of Hap.)

211 (49.2)

49 (43.4)

38 (48.7)

21 (44.7)

22 (52.4)

16 (47.1)

CHD, n (% of Hap.)

55 (12.8)

14 (12.4)

9 (11.5)

7 (14.9)

3 (7.1)

4 (11.8)

MI, n (% of Hap.)

27 (6.3)

2 (1.8)

6 (7.7)

3 (6.4)

3 (7.1)

4 (11.8)

  

P = 0.021

    
  1. • Haplotype 1: T/C at position -47, A/G at position 16, C/G at position 27.
  2. • haplotype 2: C/C at position -47, G/G at position 16, G/G at position 27.
  3. • haplotype 3: T/C at position -47, G/G at position 16, C/G at position 27.
  4. • haplotype 4: T/T at position -47, A/G at position 16, C/C at position 27.
  5. • haplotype 5: T/T at position -47, A/A at position 16, C/C at position 27.
  6. Distribution of cardiovascular risk factors, CHD and MI in the five most frequent statistical haplotypes of the three β2-adrenergic receptor polymorphisms. Comparisons between the haplotypes were performed with the χ2 test. Haplotype 1, with heterozygosity in all three polymorphisms, showed a significant (P = 0.021) lower rate of MI [n = 113, MI = 2 (1.8%]) compared with the rest of the study group [n = 316, MI = 25 (7.9%)]. This corresponds to an odds ratio of 0.21. There were no additional significant relations between clinical diagnoses and the β2-adrenergic receptor haplotypes. Furthermore, no significant differences in blood pressure, heart rate or lipid levels, respectively, existed between the different haplotypes (results not shown). Significant P factor is shown in bold.
  7. CHD, coronary heart disease; Hap., haplotype; MI, myocardial infarction.
Back to article page

BMC Medicine

ISSN: 1741-7015

Contact us